Investors Should Take Note Of Astera Labs Inc (ALAB)

Astera Labs Inc (ALAB) concluded trading on Wednesday at a closing price of $94.54, with 4.59 million shares of worth about $433.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.48% during that period and on June 11, 2025 the price saw a gain of about 3.37%. Currently the company’s common shares owned by public are about 164.91M shares, out of which, 125.46M shares are available for trading.

Stock saw a price change of -0.71% in past 5 days and over the past one month there was a price change of 17.76%. Year-to-date (YTD), ALAB shares are showing a performance of -28.62% which increased to 52.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $36.22 but also hit the highest price of $147.39 during that period. The average intraday trading volume for Astera Labs Inc shares is 3.88 million. The stock is currently trading 1.46% above its 20-day simple moving average (SMA20), while that difference is up 24.68% for SMA50 and it goes to 14.41% higher than SMA200.

Astera Labs Inc (NASDAQ: ALAB) currently have 164.91M outstanding shares and institutions hold larger chunk of about 60.35% of that.

The stock has a current market capitalization of $15.59B and its 3Y-monthly beta is at 1.39. PE ratio of stock for trailing 12 months is 402.98, while it has posted earnings per share of $0.23 in the same period. Its PEG reads 9.67 and has Quick Ratio of 13.26 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALAB, volatility over the week remained 1.89% while standing at 2.77% over the month.

Stock’s fiscal year EPS is expected to rise by 60.69% while it is estimated to increase by 27.78% in next year.

Coverage by Susquehanna stated Astera Labs Inc (ALAB) stock as a Neutral in their note to investors on May 16, 2025, suggesting a price target of $80 for the stock. On May 12, 2025, Morgan Stanley Upgrade their recommendations, while on March 14, 2025, Raymond James Initiated their ratings for the stock with a price target of $82. Stock get an Outperform rating from Northland Capital on January 28, 2025.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.